BANGALORE, India, and AURORA, Colo., April 16, 2015 /PRNewswire/ -- Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technology to empower cancer care, today announced it has opened its U.S. operations center in Aurora, Colorado. This opening is in support of the company's recent launch of the StrandAdvantage pan-cancer genomic profiling service.
Available now to physicians, StrandAdvantage was designed to accelerate the analysis of therapeutically actionable cancer genes and match them to relevant FDA-approved targeted cancer therapies and open clinical trials without the need for multiple tests.
The facilities at the Bioscience Park Center house a CLIA laboratory and customer service operations. Strand's laboratory is equipped with next generation sequencing technology, which is paired with Strand's proprietary advanced analytics and interpretation expertise to provide actionable easy-to-read genomic information in days instead of weeks. The customer service professionals facilitate clinical consultations between on-staff physicians and oncologists about the reports.
Oncologists order tests and send their tumor samples to the Aurora laboratory for sequencing. The data are then processed by powerful software that facilitate clinical interpretation in one-third of the time that it normally takes to get results from other cancer genome testing laboratories.
"The sophisticated analytical and bioinformatics infrastructure we have put into place in this new lab enhances our ability to provide oncologists with an analysis of cancer genes and therapeutic options without the need for multiple tests," said Scott Storrer, Strand's global president. "Strand was attracted to Colorado because of its excellent track record of investment in the bioscience sector and its highly educated workforce. We are excited to be part of the growing environment of innovation in Aurora."
About Strand Life Sciences
Strand Life Sciences is a genomic profiling company that uses next-generation sequencing (NGS) technology aimed at empowering cancer care. Strand's StrandAdvantage pan-cancer panels provide medical oncologists a complete understanding of genomic changes in solid tumors in days so targeted treatment plans can begin quickly. Strand's comprehensive knowledge base of genomic variants linked to FDA-approved targeted cancer therapies and drugs in open clinical trials provides clinically actionable treatment options, enabling clinicians to develop a truly personalized treatment regimen for cancer patients. For more information, please visit www.strandls.com.
Vice President, Marketing
David Schull or Todd Davenport, Ph.D.
Russo Partners, LLC
SOURCE Strand Life Sciences